Group
Anti-LAG-3 mAb
Group Profile
| Therapeutic Class | Monoclonal Antibodies (mAbs) |
| Drug Class | Checkpoint Inhibitors |
| Mechanism of Action | LAG-3 inhibitor |
| Drugs in group | Relatlimab |
Study design
RT–Drug Timing Window
Study design
RT–Drug Timing Window
Radiobiological rationale for RT–drug interaction
Theoretical immune synergy (LAG-3 upregulated post-RT). Like other checkpoint blockade, the anticipated theoretical added risk is immune-related (potentiated irAEs/pneumonitis) rather than classic in-field injury (Sinha et al., Clinical Cancer Research, 2026).
The data above refer to patients treated with Anti-LAG-3 mAb as the sole drug class,
excluding any concurrent use of drugs from other groups.
Individual Drugs
Select a drug to view its individual evidence base (drug + SBRT, no other concurrent systemic drugs). Drugs without available data are shown greyed out.